Revvity shares gain nearly 7% after major share buybacks and bullish technical signals

Revvity shares gain nearly 7% after major share buybacks and bullish technical signals
Revvity surges 6.99% today to $137.51

Revvity Inc (RVTY) surged 6.99% after the company outlined a major strategic transformation, including significant share repurchases and the acquisition of Human Cell Design. The advance is supported by a decisive break above all key moving averages, with technical signals confirming strong bullish momentum.

RVTY price prediction
24H -0.18%
$147.52
48H -0.14%
$147.59
7D -1.52%
$145.54
1M 2.29%
$151.17
3M 7.99%
$159.6
6M -3.26%
$142.97
12M 64.07%
$242.48
Current price: $147.79 -1.1300 0.76%
Closed 11/17
Daily range 146.98 Arrow from to Icon 151.15
Weekly range 146.98 Arrow from to Icon 162.33
Loading...

Highlights

  • Revvity is acquiring Human Cell Design to expand its capabilities in drug discovery and metabolic disease research.
  • The company has repurchased nearly 15% of its outstanding shares recently and sees strong demand for research reagents and software amid AI growth in pharma and biotech.
  • Shares of Revvity trade in a strong bullish trend with robust momentum, consolidating between $133.69 and $141.32, with a high probability of an upward move but early signs of overbought risk.

Share repurchase pace and AI-driven demand bolster transformation outlook

Revvity participated in the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026, where CFO Max Krakowiak discussed the company's transformation and its balanced approach to capital allocation, having repurchased nearly 15% of its outstanding shares in recent years. The company also noted robust demand for its research reagents and software driven by advancements in AI within pharmaceutical and biotech research. Additionally, Revvity announced an agreement to acquire Human Cell Design, expanding its portfolio in drug discovery and metabolic disease research.

Anton Kharitonov, expert at Traders Union, sees the recent rally as driven more by optimism than by durable fundamentals. He remains cautious despite the breakout above moving averages and strong momentum readings. The company’s heavy buybacks suggest management may lack high-return investment opportunities. Technical signals like MACD and ADX are strong, but the 'Overbought' warning and possible short-term exhaustion cannot be ignored. He warns that if Revvity fails to hold $133.69, downside risks could escalate. "Traders should be wary of chasing strength at these levels, as a pullback or reversal remains a real threat if sentiment turns."
Viktoras Karapetjanc, expert at Traders Union, interprets Revvity’s capital allocation and acquisition strategy as powerful catalysts for further growth. He believes the ongoing shift toward AI-driven solutions, highlighted at the recent conference, adds to institutional confidence. Strong demand for research reagents and software underpins robust fundamentals. Karapetjanc states that the bullish structure remains intact, with further upside likely above $141.32. "I expect this market to reward proactive investors as Revvity’s strategic moves fuel both momentum and sustainable expansion."
Jainam Mehta, market strategist, notes Revvity’s alignment above all major moving averages signals dominant upward momentum. He emphasizes the consolidation phase between $133.69 and $141.32 could set up a potential breakout. Mehta also sees the Ichimoku Kijun support as a tactical pivot for risk management. "A decisive move above resistance may invite tactical longs, while a breakdown through support could signal a short-term retreat."
Revvity Inc asset chart
Revvity Inc price dynamics. Source: TradingView.

Multitimeframe support reinforces bullish trend as overbought signals emerge

Revvity is trading firmly above its 20-day ($125.14), 50-day ($117.65), and 200-day ($103.1) moving averages, highlighting a strong bullish structure over multiple timeframes. Nearest support is at $133.69, and resistance at $141.32, with trend direction confirmed by a bullish alignment between the 50-day and 200-day averages and support from the Ichimoku Kijun at $122.59. Strong momentum is reflected in a 'Strong Buy' on the MACD and a 'Buy' signal from the ADX, while the RSI reads 59.25, indicating a 'Buy' without reaching overbought conditions. Stochastic RSI and CCI are neutral, Bull/Bear Power is positive at 2.95, and intraday action shows buyers dominating as the session approaches its high. However, an 'Overbought' warning hints at short-term exhaustion risk.

Previously it was reported that Revvity's agreement to acquire Human Cell Design introduced short-term volatility as the market weighed potential portfolio expansion. The current technical breakout and strategic capital deployment now bolster the case for sustained upside, making the $141.32 resistance level a key trigger for potential continued gains.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.